Novartis (NVS) Panoramica del titolo

Novartis AG ricerca, sviluppa, produce, distribuisce, commercializza e vende farmaci in Svizzera e a livello internazionale. Maggiori dettagli

NVS analisi fondamentale
Punteggio fiocco di neve
Valutazione	4/6
Crescita futura	2/6
Prestazioni passate	3/6
Salute finanziaria	2/6
Dividendi	5/6

Premi

Negoziato a 52.1% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 9.64% all'anno

Gli utili sono cresciuti del 5.2% nell'ultimo anno

Paga un dividendo affidabile di 3.07%

Analisi del rischio

Ha un alto livello di debito

NVS Community Fair Values

Create Narrative

See what 57 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Concorrenti di Novartis AG

Storia dei prezzi e prestazioni

Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Novartis
Prezzi storici delle azioni
Prezzo attuale dell'azione	CHF 150.80
Massimo di 52 settimane	CHF 170.46
Minimo di 52 settimane	CHF 111.06
Beta	0.49
Variazione di 1 mese	3.66%
Variazione a 3 mesi	-9.62%
Variazione di 1 anno	33.20%
Variazione a 3 anni	56.19%
Variazione a 5 anni	71.13%
Variazione dall'IPO	1,640.84%

Notizie e aggiornamenti recenti

Seeking Alpha • Apr 28

Novartis: Revenue Lags In Q1, Outlook Unchanged

Summary Novartis missed Q1 revenue and EPS estimates, but key growth products remain strong, and full-year guidance was reaffirmed. Entresto U.S. sales eroded faster than I expected, but easier Y/Y comps and robust pipeline support a return to growth. NVS's key products Kisqali, Kesimpta, Leqvio, and Pluvicto continue to outperform, and Rhapsido is off to a strong start in the CSU market with additional clinical trial readouts on the way. Avidity Biosciences acquisition adds late-stage assets, potentially boosting medium- and long-term growth and supporting valuation expansion. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Apr 28

Novartis: Revenue Lags In Q1, Outlook Unchanged

Seeking Alpha • Feb 27

Why Novartis Remains A 'Buy' After Beating Expectations Again

Summary At the end of January, Novartis pleasantly surprised me with its financial results for Q4 2024, which were achieved, in part, due to the strong performance of its oncology franchise. So, sales of Pluvicto, a medication for the treatment of prostate cancer, reached $351 million in the fourth quarter of 2024, an increase of 28.6% year-on-year. Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. In this article, dear Seeking Alpha readers, you'll know more about why I believe Novartis is an appealing stock for income-oriented investors. Read the full article on Seeking Alpha

Seeking Alpha • Feb 14

Novartis: Just What The Doctor Ordered

Summary Novartis' robust drug pipeline and strong financials, including an AA- credit rating, support an 11% annual return expectation by 2027. The company's diverse blockbuster portfolio and strategic cost management drove a 15.1% sales increase and 29% EPS growth in Q4 2024. Novartis' shares are undervalued by 11%, offering a 33% cumulative return potential through 2027, with a secure and growing 3.5% dividend yield. Despite industry risks, Novartis' growth outlook remains positive, bolstered by a solid drug roster, pipeline, and exceptional balance sheet. Read the full article on Seeking Alpha

Seeking Alpha • Jan 10

Novartis: Explaining YE24 Loss Of Momentum, Outlining Prospects For 2025

Summary Novartis experienced a strong bull run in 2024 but saw a 13% pullback post Q3 earnings, making for a potential "buy the dip" opportunity. Despite impressive Q3 financials, market concerns about 2025 patent expirations for key drugs like Entresto, Promacta, and Tasigna triggered a sell-off. Novartis' robust pipeline and new product launches are expected to offset losses from patent expirations, supporting long-term growth and a "Buy" rating. At prices below $100 per share, Novartis stock is an attractive buy, but investors need patience due to potential short-term revenue declines. Read the full article on Seeking Alpha

Seeking Alpha • Dec 13

Novartis: Time To Increase

Summary Novartis faces headwinds from Kisqali patent litigation and Entresto competition, but clinical advancements and increased mid-term sales guidance support our Buy rating. Key growth drivers include higher investments in R&D and strategic early stake acquisitions. The CEO's focus on cash generation, dividend growth, and share buybacks provides downside protection and supports EPS growth ahead of consensus. Read the full article on Seeking Alpha

Seeking Alpha • Oct 25

What To Expect When Novartis Reports Q3 2024 Results

Summary Novartis will report Q3 results next week and I expect the company to beat EPS and revenue estimates, and increase the full-year revenue and core operating income guidance. Key growth products should drive high single-digit revenue growth in the third quarter. Recent litigation updates on Entresto were negative and Novartis continues to anticipate a 2H 2025 generic launch. No major new pipeline updates are expected next week. Read the full article on Seeking Alpha

Seeking Alpha • Jul 19

Why Novartis Deserves Your Attention After Q2 2024 Results

Summary On July 18, Novartis AG released its second-quarter 2024 financial results, which were solid. The company's free cash flow was about $4.62 billion for the second quarter of 2024, up 40% year over year, primarily due to strong sales of its oncology franchise. So, Kisqali sales amounted to $717 million for the three months ended June 30, 2024, an increase of 45.4% year-on-year. On the other hand, sales of Entresto, a heart medication, were $1.9 billion in the second quarter, not only up 28% year over year but also beating my expectations. Consequently, I am initiating coverage of Novartis with a “buy” rating. Read the full article on Seeking Alpha

Seeking Alpha • May 27

Novartis: Buy This Blue-Chip Dividend Stock On Sale Now

Summary Novartis is a business that has shown tremendous resiliency, operating for hundreds of years. The multinational Swiss pharmaceutical topped the analyst consensus for revenue and core EPS in Q1. Novartis' net debt load is minimal, which justifies its prime credit rating from S&P. The big pharma company's shares could be trading at an 18% discount to fair value. Novartis could be positioned to deliver 35%+ cumulative total returns by the end of 2026. Read the full article on Seeking Alpha

Rendimenti per gli azionisti

	NVS	US Pharmaceuticals	US Mercato
7D	0.2%	2.6%	2.5%
1Y	33.2%	41.5%	26.4%

Ritorno vs Industria: NVS ha avuto una performance inferiore rispetto al US Pharmaceuticals che ha registrato un rendimento 41.5 % nell'ultimo anno.

Rendimento vs Mercato: NVS ha superato il mercato US che ha restituito 26.4 % nell'ultimo anno.

Volatilità dei prezzi

Is NVS's price volatile compared to industry and market?
NVS volatility
NVS Average Weekly Movement	3.1%
Pharmaceuticals Industry Average Movement	9.9%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.5%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: NVS non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.

Volatilità nel tempo: La volatilità settimanale ( 3% ) di NVS è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1996	75,267	Vas Narasimhan	www.novartis.com

Novartis AG ricerca, sviluppa, produce, distribuisce, commercializza e vende farmaci in Svizzera e a livello internazionale. L'azienda offre Entresto, un inibitore del recettore dell'angiotensina e dellaprilisina per il trattamento dell'insufficienza cardiaca cronica sintomatica con frazione di eiezione ridotta (HFrEF); Cosentyx per il trattamento della psoriasi a placche, dell'artrite psoriasica, della spondilite anchilosante e della spondiloartrite assiale non radiografica; Kisqali, un inibitore orale selettivo della ciclina dipendente delle chinasi 4 e 6 (CDK4/6); Promacta/Revolade per il trattamento della trombocitopenia immunitaria (ITP), della trombocitopenia e dei pazienti affetti da anemia aplastica grave (SAA); Tafinlar+Mekinist, una terapia di combinazione orale per il trattamento di pazienti affetti da alcuni tipi di tumore; e Jakavi per il trattamento della mielofibrosi, della policitemia vera e della malattia da trapianto e ospite (GvHD) acuta o cronica. Inoltre fornisce Tasigna per il trattamento della leucemia mieloide cronica positiva al cromosoma Philadelphia in fase cronica e/o accelerata; Xolair per il trattamento dell'asma allergica e dei polipi nasali o della rinosinusite cronica grave con polipi nasali; Ilaris per il trattamento delle sindromi febbrili, della malattia di Still e dell'artrite gottosa acuta; Pluvicto per il trattamento del carcinoma prostatico metastatico resistente alla castrazione; Sandostatin SC e Sandostatin LAR per il trattamento dei tumori carcinoidi dell'acromegalia e di altri tipi di tumori neuroendocrini funzionali dell'intestino e del pancreas; Zolgensma per il trattamento della causa genetica dell'atrofia muscolare spinale; Lucentis; Leqvio per la riduzione del colesterolo LDL; Lutathera; Scemblix; e Fabhalta.

Novartis AG Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Novartis con la sua capitalizzazione di mercato?
NVS statistiche fondamentali
Capitalizzazione di mercato	US$287.59b
Utili (TTM)	US$13.53b
Ricavi(TTM)	US$56.58b

21.2x

Rapporto P/E

5.1x

Rapporto P/S

NVS è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Utili e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
NVS Conto economico (TTM)
Ricavi	US$56.58b
Costo del fatturato	US$13.83b
Profitto lordo	US$42.75b
Altre spese	US$29.21b
Utili	US$13.53b

Ultimi utili riportati

Mar 31, 2026

Prossima data di guadagno

Jul 21, 2026

Utile per azione (EPS)	7.09
Margine lordo	75.55%
Margine di profitto netto	23.92%
Rapporto debito/patrimonio netto	115.8%

Come si è comportato NVS nel lungo periodo?

Vedi performance storica e confronto

Dividendi

3.1%

Rendimento attuale del dividendo

66%

Rapporto di remunerazione

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2026/05/26 04:56
Prezzo dell'azione a fine giornata	2026/05/26 00:00
Utili	2026/03/31
Utili annuali	2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Novartis AG è coperta da 58 analisti. 20 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
John Eade	Argus Research Company
Odile Rundquist	Baader Helvea Equity Research
Gerhard Schwarz	Baader Helvea Equity Research

Novartis (NVS) Panoramica del titolo

Premi

Analisi del rischio

Concorrenti di Novartis AG

Merck

Johnson & Johnson

Bristol-Myers Squibb

Pfizer

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Novartis Announces New Data For Pluvicto In Metastatic Hormone-Sensitive Prostate Cancer

Novartis Ag Reaffirms Earnings Guidance for the Full Year 2026

Novartis Receives European Commission Approval for Rhapsido as First Oral Targeted Treatment for Chronic Spontaneous Urticaria

Novartis: Revenue Lags In Q1, Outlook Unchanged

Novartis Announces Coartem Baby Receives Who Prequalification

Novartis Announces Expansion of Community Health Programs to Close Gaps in Heart Disease and Cancer Care

Recent updates

Novartis Announces New Data For Pluvicto In Metastatic Hormone-Sensitive Prostate Cancer

Novartis Ag Reaffirms Earnings Guidance for the Full Year 2026

Novartis Receives European Commission Approval for Rhapsido as First Oral Targeted Treatment for Chronic Spontaneous Urticaria

Novartis: Revenue Lags In Q1, Outlook Unchanged

Novartis Announces Coartem Baby Receives Who Prequalification

Novartis Announces Expansion of Community Health Programs to Close Gaps in Heart Disease and Cancer Care

Novartis AG (SWX:NOVN) entered into a definitive agreement to acquire Pikavation Therapeutics, Inc. from Synnovation Therapeutics, Inc. for $3 billion.

Novartis Announces FDA Approval for Cosentyx for Pediatric Patients with Moderate to Severe Hidradenitis Suppurativa

Novartis AG Approves Dividend for 2025, Payable from March 12, 2026

Novartis Receives Positive Chmp Opinion for Remibrutinib in Chronic Spontaneous Urticaria (Csu)

Novartis Announces Multiple US Real-World Studies Delivering New Insights Across Metastatic Prostate Cancer

Novartis Presents Rhapsido®? (Remibrutinib) Data At Aaaai, Showing Potential Beyond Chronic Spontaneous Urticaria (Csu)

Chryscapital Fund X, a fund managed by ChrysCapital Advisors LLP and Two Infinity Partners entered into the Agreement to acquire to acquire 14.23% stake in Novartis India Limited (BSE:500672) from Novartis AG (SWX:NOVN) for INR 2.5 billion.

Novartis Announces Positive Topline Results from its Pivotal Phase III Remind Trial of Oral Remibrutinib in Chronic Inducible Urticaria (CIndU)

Novartis Announces Final Results from the Phase III ALIGN Study

Novartis Canada Receives Positive Draft Recommendation from Canada's Drug Agency for All Eligible Early Breast Cancer Patients At High Risk of Recurrence

Novartis AG, Annual General Meeting, Mar 06, 2026

Novartis Ag Reports Impairment Charges for the Fourth Quarter Ended December 31, 2025

Novartis Ianalumab Receives Fda Breakthrough Therapy Designation for Sjogren's Disease

Novartis Announces Results from One in Four Patients with Hectaree (ribociclib) Plus Endocrine Therapy (ET)

Novartis Receives FDA Approval for Itvisma®?, the Only Gene Replacement Therapy for Children Two Years and Older, Teens, and Adults with Spinal Muscular Dystrophy (SMA)

Novartis AG Provides Sales Guidance for 2025-2030

Novartis Announces Positive Results from KALUMA, a Phase III Study for New Malaria Treatment KLU156

Novartis AG Presents New Iianalumab Data in Sjogren's Disease

Novartis AG (SWX:NOVN) completed the acquisition of 92.94% in Tourmaline Bio, Inc. (NasdaqGS:TRML).

Novartis Showcases Significant Immunology Advancements in ACR Congress with New Data in Complex Autoimmune Diseases

Novartis Cosentyx Metals in Phase III Trial in Patients with Polymyalgia Rheumatica (PMR)

Novartis Presents New Pluvicto (Lutetium (177Lu) Vipivotide Tetraxetan) Data from the Phase III PSMAddition Trial in a Presidential Symposium at the European Society for Medical Oncology Congress 2025

Novartis Announces Results from Five-Year Analysis of Pivotal Phase III NATALEE Trial of Kisqali (Ribociclib)

Samsung Electronics Co., Ltd. (KOSE:A005930) completed the acquisition of Xealth Inc.

Novartis Scemblix Receives Positive CHMP Opinion for the Treatment of Adults with Newly Diagnated CML

Novartis Announces Positive Final Results from APPLAUSE-IgAN, A Phase III Study Evaluating Fabhalta®? (Iptacopan) in Adults Living with IgAN

Novartis AG Receives FDA Approval for Rhapsido®? (Remibrutinib)

Novartis to Launch Direct-To-Patient Platform for Cosentyx (Secukinumab) in the US

Novartis to Showcase Transformative Data in Advanced Prostate and Early Breast Cancer At Esmo 2025

Novartis Announces New Data from Two Kesimpta®? (Ofatumumab) Studies in Relapsing Multiple Sclerosis

Novartis AG (SWX:NOVN) entered into an agreement to acquire Tourmaline Bio, Inc. (NasdaqGS:TRML) for $1.2 billion.

Novartis Announces Bothianalumab Phase III Clinical Trials Met Primary Endpoint in Patients with Sjogren's Disease

Novartis Reportedly Weighs Deal for Biotech Avidity to Boost Drug Pipeline

Novartis AG Revises Earnings Guidance for Full Year 2025

Novartis Announces Executive Committee Changes

Samsung Electronics Co., Ltd. (KOSE:A005930) signed an agreement to acquire Xealth Inc.

Novartis Provides Update on Phase III GCAptAIN Study of Cosentyx in Giant Cell Arthritis (GCA)

Novartis AG (SWX:NOVN)completed the acquisition of Regulus Therapeutics Inc. (NasdaqCM:RGLS).

Novartis Announces Topline Results from Pre-Specified Interim Analysis of the Phase III PSMAddition Trial

Novartis AG (SWX:NOVN) entered into an agreement and plan of merger to acquire Regulus Therapeutics Inc. (NasdaqCM:RGLS) for approximately $470 million.

Novartis AG (SWX:NOVN) completed the acquisition of an unknown majority stake in Anthos Therapeutics, Inc. from Blackstone Life Sciences.

Novartis Receives FDA Accelerated Approval for Vanrafia (Atrasentan) for the Reduction of Proteinuria in Adults with Primary Immunoglobulin A Nephropathy

Market Volatility Derails Novartis' Plan to Sell Stake in its India Arm

Novartis Announces Executive Changes

Fda Approves Novartis Radioligand Therapy Pluvicto for Early Use Before Chemotherapy in Psma-Positive Metastatic Castration-Resistant Prostate Cancer

New Novartis Phase III Data Demonstrates Meaningful Efficacy and Safety Results of Intriathecal Onasemnogeneabeparvovec in Broad Patient Population with SMA

Novartis AG Approves Dividend for 2024, Payable from March 13, 2025

Novartis Oral Fabhalta (Iptacopan) Receives Positive CHMP Opinion for the Treatment of Adults Living with C3 Glomerulopathy (C3g)

Why Novartis Remains A 'Buy' After Beating Expectations Again

Novartis: Just What The Doctor Ordered

Novartis AG (SWX:NOVN) agreed to acquire an unknown majority stake in Anthos Therapeutics, Inc. from Blackstone Life Sciences for approximately $3.1 billion.

Novartis AG to Report Q2, 2025 Results on Jul 17, 2025

Novartis: Explaining YE24 Loss Of Momentum, Outlining Prospects For 2025

Novartis Announces Positive Topline Results from the Phase III Steer Study

Novartis: Time To Increase

Novartis Inc. Announces Results from an Updated Analysis of the Pivotal Phase III Natalee Trial of Kisqali®? (ribociclib)

Novartis Announces Positive, Long-Term Results from the Pivotal Phase III ASC4FIRST Trial with Scemblix (asciminib)